Amersin Life Sciences Corporation Announces New Trading Symbol and Completion of Name Change
Amersin Life Sciences Corporation (formerly Hubei Pharmaceutical Group Ltd. OTCBB:HBEI, CUSIP 44352P106) announced today that it has completed its name change and been assigned a new trading symbol and CUSIP number.
New York, NY (PRWEB via NSTI)
January 14, 2005 -- Amersin Life Sciences Corporation (formerly Hubei
Pharmaceutical Group Ltd. OTCBB:HBEI, CUSIP 44352P106) announced today that it
has completed its name change and been assigned a new trading symbol and CUSIP
number. Effective at the open of markets on January 14th, 2005 the new trading
symbol for Amersin Life Sciences Corporation in the United States will be AMLS.
The new CUSIP number is 03075R104.
Amersin Life Sciences Corporation is
engaged in the acquisition and vertical integration of operating subsidiaries
and controlling joint venture interests in China to include all facets of
pharmaceutical life sciences from raw materials through dosage form production
and distribution. The company owns a controlling interest in a profitable
pharmaceutical factory, Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd. located
in Guangshui City, Hubei Province, China. It is a continuation and expansion of
the dosage division previously owned by Hubei Benda Science and Technology Co.
Ltd. whose management and controlling partners hold a minority interest and
provide ongoing operational management. This is characteristic of our
acquisition strategy, providing continuity of the successful management team and
other resources while looking for opportunities to streamline operations and
broaden market penetration through strategic relationships with other
subsidiaries or independent organizations in the life sciences field. Our
business plan positions Amersin as a holding company, providing investment
capital and a western perspective on the development of brand and market share.
We act as a catalyst in identifying pharmaceutical enterprises as acquisition
targets to build and integrate their areas of specialization into a synergetic
whole that exceeds the achievements of the individual operating units. We are
focused on building investor equity through strategic acquisition and vertical
integration.
“The name change is an important step forward in our
corporate development, more closely reflecting the goals and diversity of our
business plan,” commented Howard Milne, director of corporate communications.
“It more clearly differentiates the US holding company and its’ western
management style from the operating subsidiaries in China. Completion paves the
way to broaden our investor relations activities, drawing attention to our
successful track record and consistent quarterly profits, paving the way for
future expansion and illustrating what we believe will be seen as an attractive,
early stage opportunity to participate in the pharmaceutical life sciences
sector in the booming Chinese economy.”
Amersin shares are listed in
Germany on the Frankfurt Stock Exchange under the trading symbol HUQ and in the
United States on the OTCBB under the symbol AMLS. Additional information is
available via our website at http://www.amersin.com.
"Safe Harbor” Statement: This
news release contains certain "forward-looking" statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, Section 21E of the
Securities Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from the
forward-looking statements contained herein. Detailed information about many
risk factors are set forth in Amersin’s periodic filings with the Securities and
Exchange Commission including, but not limited to, those risks and uncertainties
listed in the sections entitled "Cautionary Note Regarding Forward-Looking
Statements” and “Management’s Discussion and Analysis” in Amersin’s most recent
Quarterly Report on Form 10-QSB. All documents are available through the SEC's
Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov or the Amersin
web site at http://www.amersin.com. Amersin is under no obligation, and
expressly disclaims any obligation, to update or alter its forward-looking
statements, whether as a result of new information, future events or
otherwise.
For more information, contact:
Corporate
Communications:
Amersin Life Sciences Corporation
Howard Milne,
604-881-2899 ext 220
Fax: 604-881-2892
e-mail protected from spam
bots
# # #
Source : http://www.prweb.com/releases/2005/1/prweb197804.htm